Victory Capital Management
UBX

Victory Capital Management’s Unity Biotechnology UBX Stock Holding History

Victory Capital Management’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,401
Closed -$6K – 2709
2022
Q3 		$6K Buy
+1,401
New +$8.84K ﹤0.01% 2676
2020
Q2 		– Sell
-653
Closed -$38K – 3245
2020
Q1 		$38K Buy
+653
New +$41.2K ﹤0.01% 2875
2019
Q4 		– Sell
-348
Closed -$21K – 3248
2019
Q3 		$21K Buy
+348
New +$24.6K ﹤0.01% 3028

Other funds holding UBX

AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management's UBX Position: Q4 2022 in Review

Victory Capital Management sold out of Unity Biotechnology (UBX) in Q4 2022, closing a stake of 1,401 shares — an estimated $6K sold.

Victory Capital Management first reported a position in UBX in Q3 2019 and held it in 3 quarters. The position peaked at $38K in Q1 2020. 54 funds tracked by Wall St. Rank hold UBX as of Q4 2022.

  • Victory Capital Management reported no remaining Unity Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Victory Capital Management sold 1,401 Unity Biotechnology shares in Q4 2022, an estimated $6K.
  • Victory Capital Management first reported a position in Unity Biotechnology in Q3 2019 and held it in 3 quarters.
  • Victory Capital Management's Unity Biotechnology position peaked at $38K in Q1 2020.
  • 54 funds tracked by Wall St. Rank held Unity Biotechnology as of Q4 2022.

Based on Victory Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.